Lessons from the withdrawal of rofecoxib

BMJ. 2004 Oct 16;329(7471):867-8. doi: 10.1136/bmj.329.7471.867.

Abstract

Patients would be safer if drug companies disclosed adverse events before licensing

Publication types

  • Editorial

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects*
  • Cyclooxygenase Inhibitors / adverse effects*
  • Drug Approval*
  • Humans
  • Lactones / adverse effects*
  • Sulfones

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Cyclooxygenase Inhibitors
  • Lactones
  • Sulfones
  • rofecoxib